Imugene Limited (ASX:IMU) is a clinical stage immuno-oncology company involved in developing a range of new and novel immunotherapies that seek to activate a cancer patient’s immune system to detect and eliminate tumours. Over the years, it has grown tremendously to become one of the top three largest biotech companies in Australia.
Imugene bringing effective new treatments and options to cancer patients
GET A FREE STOCK REPORT
Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.
Recent Articles
Sponsored
Platina Resources (ASX:PGM) announces $2.2M placement to amp up gold projects
- August 12, 2022 03:05 PM AEST
- Mohammad Zaid
Stock Market
ASX 200 to fall at open; ResMed, IAG’s results ahead
- August 12, 2022 08:17 AM AEST
- Ashish
_08_12_2022_02_07_30_361093.jpg "Why ASX Stocks Fonterra, IAG, ResMed, Baby Bunting On investors Radar on 12 August?")
_08_12_2022_01_33_45_616121.png "ASX 200 to fall at open; ResMed, IAG’s results ahead")
_08_12_2022_01_27_48_757696.png "High-End brands moves towards Web3 | Which companies came out with their NFTs?")
_08_11_2022_17_10_30_195037.png "Why are Video Gaming Giants suffering?")
Be the First to Comment